• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evaluation of pharmacoinvasive strategy versus percutaneous coronary intervention in patients with acute myocardial infarction with ST segment elevation at the National Institute of Cardiology (PHASE-MX).
Conclusion: In Mexico, only 5 out of 10 patients with STEMI have access to reperfusion therapy. Pharmacoinvasive strategy is takes advantage of the accessibility of fibrinolysis and the effectiveness of PCI. The present research protocol aims to provide information that serves as a link between information derived from controlled clinical trials and records derived from real world experience. PMID: 32459215 [PubMed - as supplied by publisher]
Source: Archivos de Cardiologia de Mexico - May 28, 2020 Category: Cardiology Authors: Baeza-Herrera LA, Araiza-Garaygordobil D, Gopar-Nieto R, Raymundo-Martínez GI, Loáisiga-Sáenz A, Villalobos-Flores A, Martínez-Ramos M, Torres-Araujo LV, Pohls-Vázquez R, Luna-Herbert A, Alonso-Vázquez A, Delgado-Cruz IV, Cabello-López A, Martínez Tags: Arch Cardiol Mex Source Type: research

Evaluation of pharmacoinvasive strategy versus percutaneous coronary intervention in patients with acute myocardial infarction with ST-segment elevation at the National Institute of Cardiology (PHASE-MX).
Conclusion: In Mexico, only 5 out of 10 patients with STEMI have access to reperfusion therapy. Pharmacoinvasive strategy is takes advantage of the accessibility of fibrinolysis and the effectiveness of PCI. The present research protocol aims to provide information that serves as a link between information derived from controlled clinical trials and records derived from real world experience. PMID: 32897264 [PubMed - as supplied by publisher]
Source: Archivos de Cardiologia de Mexico - September 9, 2020 Category: Cardiology Authors: Baeza-Herrera LA, Araiza-Garaygordobil D, Gopar-Nieto R, Raymundo-Martínez GI, Loáisiga-Sáenz A, Villalobos-Flores A, Martínez-Ramos M, Torres-Araujo LV, Pohls-Vázquez R, Luna-Herbert A, Alonso-Vázquez A, Delgado-Cruz IV, Cabello-López A, Martínez Tags: Arch Cardiol Mex Source Type: research

Characteristics and Outcomes of Patients 80 Years and Older Hospitalized With Coronavirus Disease 2019 (COVID-19)
Patients older than 65 years hospitalized with COVID-19 have higher rates of intensive care unit admission and death when compared with younger patients. Cardiovascular conditions associated with COVID-19 include myocardial injury, acute myocarditis, cardiac arrhythmias, cardiomyopathies, cardiogenic shock, thromboembolic disease, and cardiac arrest. Few studies have described the clinical course of those at the upper extreme of age. We characterize the clinical course and outcomes of 73 patients with 80 years of age or older hospitalized at an academic center between March 15 and May 13, 2020. These patients had multiple ...
Source: Cardiology in Review - December 13, 2020 Category: Cardiology Tags: Review Articles Source Type: research

Clinical features and outcomes between African American and Caucasian patients with Takotsubo Syndrome.
CONCLUSIONS: Despite experiencing the same rate of in-hospital complications, the clinical profiles of AA patients are distinct from CAU patients admitted for TS, and clinical variables correlated with worse in-hospital outcomes also differ by race. PMID: 33427424 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - January 13, 2021 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Contemporary device management of cardiogenic shock following acute myocardial infarction
AbstractDespite advances in the overall management of acute myocardial infarction (AMI), cardiogenic shock in the setting of AMI (CS-AMI) continues to be associated with poor patient outcomes. There are multiple devices that can be used in CS-AMI to support the failing circulation, although their utility in improving outcomes as compared with conventional pharmacotherapy of vasopressors and inotropes remains to be established. This contemporary review provides an update on the evidence base for each of these techniques. In CS-AMI, acute thrombotic occlusion of a major epicardial artery leads to hypoxia and myocardial ischa...
Source: Heart Failure Reviews - March 3, 2021 Category: Cardiology Source Type: research

Revascularization Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock: Results from the Portuguese Registry on Acute Coronary Syndromes
Conclusions: Among patients with MI, CS, and MVD included in the ProACS, there was no significant difference between complete and incomplete revascularization during the index hospitalization regarding the occurrence of in-hospital death or MI. (Arq Bras Cardiol. 2021; 116(5):867-876)
Source: Arquivos Brasileiros de Cardiologia - May 17, 2021 Category: Cardiology Source Type: research

Analysis of Revascularization Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock - Results from the Portuguese Registry on Acute Coronary Syndromes
Conclusions: Among patients with MI, CS, and MVD included in the ProACS, there was no significant difference between complete and incomplete revascularization during the index hospitalization regarding the occurrence of in-hospital death or MI. (Arq Bras Cardiol. 2021; 116(5):867-876)
Source: Arquivos Brasileiros de Cardiologia - May 17, 2021 Category: Cardiology Source Type: research

Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research

A case series analysis on the clinical experience of Impella 5.5 ® at a large tertiary care centre
ConclusionsIn this early experience of the pVAD 5.5, procedural and device-related complications were observed but were manageable, and overall survival was high in this critically ill cohort, particularly when the device was used as a bridge to other therapies.
Source: ESC Heart Failure - August 17, 2021 Category: Cardiology Authors: Peter J. Kennel, Heidi Lumish, Yuji Kaku, Justin Fried, Ajay J. Kirtane, Dimitri Karmpaliotis, Hiroo Takayama, Yoshifumi Naka, Gabriel Sayer, Nir Uriel, Koji Takeda, Amirali Masoumi Tags: Original Research Article Source Type: research

Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16